title: [Antibiotic treatment of appendicular peritonitis in children: is the oral route done?].
abstract: The use of intravenously administered antibiotics has several disadvantages including hospitalization costs, infectious risk, and patient discomfort. The objective of this study was to estimate the proportion of children receiving intravenous antibiotic therapy (IV), for whom there was a switch to an oral route conforming to the criteria established by the American Pediatric Surgical Association (APSA). A cohort of 100 children hospitalized for acute appendicitis with generalized peritonitis or abscess were analyzed. In this study, we compared the criteria of switching to an oral route as recommended by the APSA (disappearance of the pain, normalization of white blood cells, afebrile for 48 hours, return to bowel function) and by reports from the literature (afebrile, tolerating regular diet). In 47.5% of the children, there was a switch to an oral route conforming to the APSA recommendations. In children having a late switch, the average duration of the IV treatment was of 7.6 ± 3.6 days associated with 62 days of avoidable IV antibiotics. The duration of hospitalization and antibiotic treatment was significantly higher in children having a late switch (P=0.04; P=0.01, respectively). Concerning the criteria reported in the literature, 14.5% of children were not switched to an oral route. Meeting the criteria from the literature would have resulted in 199 days of avoidable IV antibiotics. A significant number of days of IV antibiotics could have been avoided. However, the large number of exclusion criteria in the APSA analysis suggests that practitioners do not follow these recommendations or objective criteria. The criteria proposed in the literature could decrease the duration of IV antibiotics and the associated hospitalization costs.
authors.affiliation: Service de pharmacie, groupement hospitalier Necker-Enfants-Malades, AP-HP, 149, rue de Sèvres, 75743 Paris cedex 15, France. aurore.berthe84@gmail.com
authors.forename: A
authors.initials: A
authors.lastname: Berthe-Aucejo
authors.forename: M
authors.initials: M
authors.lastname: Postaire
authors.forename: A
authors.initials: A
authors.lastname: Cheikhlard
authors.forename: J-R
authors.initials: JR
authors.lastname: Zahar
authors.forename: P
authors.initials: P
authors.lastname: Bourget
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001064:Appendicitis / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D005260:Female; D005602:France; D006801:Humans; D007262:Infusions, Intravenous; D007902:Length of Stay; D008297:Male; D010538:Peritonitis / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D012189:Retrospective Studies
chemical_list: D000900:Anti-Bacterial Agents